Placental malaria, especially when associated with a local inflammatory response termed intervillositis, can cause foetal growth restriction leading to low birth weight. We have identified decreased transplacental amino acid transport capacity as a mechanism leading to foetal growth restriction in placental malaria. The mechanistic target of rapamycin (mTOR) pathway regulates placental amino acid uptake in response to various environmental cues.
We hypothesize that the impaired amino acid transport capacity observed in placental malaria infection with intervillositis is mediated by a down-regulation of placental mTOR signalling activity, contributing to poor foetal growth.
Term villous tissue biopsies from uninfected placentas and from infected placentas with and without intervillositis (n=4/group) from Malawian women were used. We assessed mTOR signalling activity by quantifying the expression and phosphorylation levels of downstream effectors of the mTOR pathway namely ribosomal protein S6 (rpS6) and eukaryotic initiation factor 4E binding protein 1 (4EBP-1) using western blot.
The mTOR activity appears to be
down-regulated in placental malaria especially with intervillositis. Relative
phosphorylation levels of 4EBP-1 are significantly lower in infected placentas
compared to uninfected tissues (p = 0.04) while the lowest relative phosphorylation
levels of rpS6 are specifically found in inflamed placentas (p = 0.04) compared
to placentas without inflammation. Relative phosphorylation levels of rpS6
negatively correlate with the severity of the inflammation measured as the percentage
of monocytes in placental blood
(R = -0.85; p = 0.007) and positively with birth weight (R = 0.75; p = 0.03).
These results suggest that placental malaria, especially with intervillositis, is associated with a down-regulation of placental mTOR signalling activity, supporting foetal growth restriction.
Identifying mTOR as a central regulator of foetal growth in placental malaria would pave the way for innovative intervention strategies, including supplementation with nutrients that specifically activate placental mTOR signalling, to improve foetal growth and pregnancy outcomes in women with malaria.